Actively Recruiting
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2025-09-23
796
Participants Needed
2
Research Sites
641 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to learn if combined treatment of levothyroxine and hydroxychloroquine would improve the live birth of euthyroid women with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss. Researchers will compare combined treatment of levothyroxine and hydroxychloroquine to a treatment of levothyroxine alone to see if combined treatment works to improve live birth of euthyroid participants with thyroid peroxidase antibodies and unexplained recurrent pregnancy loss. Participants will: * Receive combined treatment of levothyroxine and hydroxychloroquine or treatment of levothyroxine alone every day at least 8 weeks before pregnancy, and continue their treatment till the end of pregnancy. * Visit the clinic 4 weeks and 8 weeks after their treatments, and every 12 weeks before they get pregnant for checkups and tests. During their pregnancy, they will visit the clinic before gestation of 12 weeks, and will be followed up with phone call in the second trimester and after parturition.
CONDITIONS
Official Title
Effect of HCQ Combined With LT4 on LBR in Euthyroid Women With URPL and TPO-Ab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women with history of two or more pregnancy loss with the same male partner (including biochemical pregnancies).
- Karyotype analyses show no pathological abnormalities in each individual of the recruited couple.
- Women aged between 20 and 40 years old (including 20 and 40).
- Lupus anticoagulant (LA), anticardiolipin antibody (ACA), and anti-beta2-glycoprotein I antibodies (anti-b22-GP1 Ab) tests are all negative.
- It is confirmed by ultrasound or hysteroscopy that there are no pathological lesions that affect the morphology of the uterine cavity (such as submucosal uterine fibroids, uterine malformations).
- TPO-Ab positive (TPO-Ab > 60 IU/mL using the Siemens kit of electrochemiluminescence method, or TPO-Ab > 34 IU/mL using the Roche kit of chemiluminescence method).
- Biochemically euthyroid. TSH, free triiodothyronine (FT3), and free thyroxine (T4) are all within the reference range of corresponding laboratory testing in each research center.
You will not qualify if you...
- Rheumatic diseases, such as systemic lupus erythematosus, undifferentiated connective tissue disease, etc.
- Metabolic or endocrine diseases, such as diabetes.
- Abnormal renal function: plasma creatinine level 20130 bcmol/L or abnormal liver function: alanine aminotransferase 2058U/L or aspartate aminotransferase 2058U/L.
- Hypertension and malignant tumors.
- Under treatment with glucocorticoids or immunosuppressor, including cyclosporine, azathioprine, prednisone, and methylprednisolone.
- Body Mass Index (BMI) >28kg/m2.
- Past history of hyperthyroidism, hypothyroidism, and thyroid malignant tumors;
- Allergy to 4-aminoquinoline compound, or those with retinal or visual field lesions caused by 4-aminoquinoline compound.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Sun Yat-Sen Memorial Hospital
Guangzhou, Guangdong, China, 510000
Actively Recruiting
2
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou, Guangdong, China, 510120
Not Yet Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here